about
Synthesis of new 2-arylamino-6-trifluoromethylpyridine-3-carboxylic acid derivatives and investigation of their analgesic activityNew therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonistsAdenosine A2A receptor antagonists and Parkinson's disease: state of the art and future directionsAnxiolytic-like effects of N,N-dialkyl-2-phenylindol-3-ylglyoxylamides by modulation of translocator protein promoting neurosteroid biosynthesisNicotinamide prevents the long-term effects of perinatal asphyxia on apoptosis, non-spatial working memory and anxiety in rats.Caffeine and the dopaminergic system.Dopamine and adenosine receptor interaction as basis for the treatment of Parkinson's disease.Perinatal asphyxia: current status and approaches towards neuroprotective strategies, with focus on sentinel proteins.A(2A) Receptor Antagonism and Dyskinesia in Parkinson's DiseaseLate-onset Parkinsonism in NFκB/c-Rel-deficient miceHow reliable is the behavioural evaluation of dyskinesia in animal models of Parkinson's disease?The 6-hydroxydopamine model of Parkinson's disease.Direct and indirect striatal efferent pathways are differentially influenced by low and high dyskinetic drugs: behavioural and biochemical evidence.Role of movement in long-term basal ganglia changes: implications for abnormal motor responses.Biomarkers for evaluation of clinical efficacy of multipotential neuroprotective drugs for Alzheimer's and Parkinson's diseases.Adenosine, adenosine A 2A antagonists, and Parkinson's disease.Adenosine A2A receptors and Parkinson's disease.Methylxanthines and drug dependence: a focus on interactions with substances of abuse.A critical evaluation of behavioral rodent models of motor impairment used for screening of antiparkinsonian activity: The case of adenosine A(2A) receptor antagonists.Dyskinesia in Parkinson's disease: mechanisms and current non-pharmacological interventions.D1-Receptor-related priming is attenuated by antisense-meditated 'knockdown' of fosB expression.Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease.Dopamine/glutamate interaction as studied by combining turning behaviour and c-Fos expression.Biomarkers for prediction and targeted prevention of Alzheimer's and Parkinson's diseases: evaluation of drug clinical efficacy.MPTP-induced dopamine neuron degeneration and glia activation is potentiated in MDMA-pretreated mice.Adenosine A2 receptors interact negatively with dopamine D1 and D2 receptors in unilaterally 6-hydroxydopamine-lesioned rats.Can dietary substances protect against Parkinson's disease? The case of caffeine.Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression.A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.Caffeine enhances astroglia and microglia reactivity induced by 3,4-methylenedioxymethamphetamine ('ecstasy') in mouse brain.Alterations in GAD67, dynorphin and enkephalin mRNA in striatal output neurons following priming in the 6-OHDA model of Parkinson's disease.Interaction between dopamine and adenosine A2A receptors as a basis for the treatment of Parkinson's disease.Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-dopa and A2A receptor blockade plus L-dopa in dopamine-denervated rats.Modification of adenosine extracellular levels and adenosine A(2A) receptor mRNA by dopamine denervation.Autoradiographic localization of [3H] [MePhe3,D-Pro4]morphiceptin ([3H]PL017) to mu opioid receptors in rat brain.EEG modifications in the cortex and striatum after dopaminergic priming in the 6-hydroxydopamine rat model of Parkinson's disease.Subchronic caffeine exposure induces sensitization to caffeine and cross-sensitization to amphetamine ipsilateral turning behavior independent from dopamine release.Microglial and astroglial activation by 3,4-methylenedioxymethamphetamine (MDMA) in mice depends on S(+) enantiomer and is associated with an increase in body temperature and motility.Selective modifications in GAD67 mRNA levels in striatonigral and striatopallidal pathways correlate to dopamine agonist priming in 6-hydroxydopamine-lesioned rats.Blockade of A2A receptors plus l-DOPA after nigrostriatal lesion results in GAD67 mRNA changes different from l-DOPA alone in the rat globus pallidus and substantia nigra reticulata.
P50
Q28199134-F34952E8-6CE5-4765-B1D6-13CAD0CF221DQ28258352-7F050CF6-C4DA-4BC2-8C39-136C66EFAB0AQ28283008-99F3105E-66AC-4728-A9C9-4DD5683AE260Q28291960-7D73E5F2-1874-4D09-99B2-FCF551875A52Q33518638-C1E4EBAC-B657-49C4-A3BF-C5D901FE17DCQ34403052-A69352A1-3E1B-4218-B8E7-A749A2183A79Q34539209-226B4D7B-1F23-4B3B-947F-9C7126653567Q35795263-19756F4C-2673-43C2-B7EF-763BB21DB275Q36057652-0A628808-1813-4433-879F-F516C2FF5756Q36218699-F83DFFFD-F5E2-40BC-A1EB-B2B6A4668243Q36581230-2A2E9E22-C4AB-49B1-8AA0-D15BD9B71770Q36797981-348C6D5F-A6D9-4786-B766-35DD4E070D5FQ37201154-3775375E-69CB-45C4-A128-9F1A9E2B06EFQ37249385-DEA83E53-D497-424D-A4C4-D3A04E639F89Q37358672-D8148DA1-ECF9-407F-B362-1BB8E70110D5Q37484685-40B473B3-9CF2-4307-A77E-A5F82FF632F8Q37565218-0B388324-3969-4FE5-914F-0299BA07A30DQ37791061-B3390FDB-71EA-47F9-9D5D-CD01609B9CD0Q38169996-F7905E58-0DB7-4FA2-BF20-EABD29771E87Q38207680-4B52C569-C621-4609-AC39-AB984626CEC3Q38338409-B256A233-159D-48B7-8D94-C58BBFC06EDEQ38553874-35CA2EA3-6B23-4877-B3A2-6C7D6FC4F3F0Q41509299-71455B84-BF6C-4B82-BD53-513B71B1B140Q42126269-3C9967A8-7343-410A-A369-22A9B35BE574Q42446212-956E7827-43A5-41AC-AFF9-B164CB51B156Q42491104-DFFC6C74-476C-441F-BB25-D7A56425C2B4Q42957829-9C66F6F8-478B-46AC-A711-8312E8A9C0F5Q43069227-1F3CC9C2-DC95-4577-AB81-2F099B857ADFQ43232822-70D5037A-C4D6-4DF3-9CD0-45D8FD552E55Q43250794-FC6C96D1-31EF-47C3-A853-4F679C446AAAQ43696874-56E39E6E-934E-4346-9B07-B7134F6F35A3Q43696891-B1C8E122-2C5C-44C5-B6C8-0F92AEB7DE91Q43959920-9729ADE6-CBB5-433A-8862-8449123DA74DQ44050773-ECFD92D4-C3C4-4E52-929C-DA409EA024FAQ44347714-6C7F9B4F-18D8-488A-958F-89BCA039FB46Q44413937-DD305B7C-8237-4A17-91F0-4AFA8BE6A90CQ44515045-8ABD0BDE-A3BC-472C-B4B4-99C8B1E0BFA2Q44599215-3DB4D652-B396-46EE-B495-07F08FF3A0C1Q44658133-20BB7F8D-CE46-4CCA-B490-DC38CFC4BCD1Q44760113-3B75826F-9641-419A-8E47-DF2477DE43D3
P50
description
researcher, ORCID id # 0000-0003-0394-5782
@en
wetenschapper
@nl
name
Micaela Morelli
@ast
Micaela Morelli
@en
Micaela Morelli
@es
Micaela Morelli
@nl
type
label
Micaela Morelli
@ast
Micaela Morelli
@en
Micaela Morelli
@es
Micaela Morelli
@nl
altLabel
Morelli M
@en
micaela morelli
@en
prefLabel
Micaela Morelli
@ast
Micaela Morelli
@en
Micaela Morelli
@es
Micaela Morelli
@nl
P106
P1153
7103166484
P21
P31
P4012
P496
0000-0003-0394-5782